Flortaucipir F 18

Drug Profile

Flortaucipir F 18

Alternative Names: 18F-AV-1451; [18F] T 807; [F-18]T807; F-18-AV-1451; Fluorine 18 AV 1451; T807

Latest Information Update: 27 Feb 2017

Price : $50

At a glance

  • Originator Siemens Medical Solutions
  • Developer Avid Radiopharmaceuticals
  • Class Imaging agents; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Alzheimer's disease
  • Phase II Brain injuries; Cognition disorders; Dementia; Depressive disorders; Neurodegenerative disorders; Progressive supranuclear palsy

Most Recent Events

  • 10 Feb 2017 Avid Radiopharmaceuticals plans a phase I trial for Cognitive decline in USA (NCT03052972)
  • 31 Jan 2017 Avid Radiopharmaceuticals plans a phase I trial for frontotemporal Dementia (Diagnosis) (IV) (NCT03040713)
  • 09 Jan 2017 CHRU de Tours plans a phase II trial for Alzheimer's disease (In adults, In the elderly, Diagnosis, In healthy volunteers) in France (NCT03022968)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top